HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
AMMECR1
AMMECR nuclear protein 1
Chromosome X Β· Xq23
NCBI Gene: 9949Ensembl: ENSG00000101935.13HGNC: HGNC:467UniProt: A0A0S2Z4V0
32PubMed Papers
22Diseases
0Drugs
14Pathogenic Variants
FUNCTIONAL ROLE
Highly Constrained
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein bindingnucleusnucleoplasmAlport syndrome - intellectual disability - midface hypoplasia - elliptocytosisShort staturenephrocalcinosisneurodegenerative disease
✦AI Summary

AMMECR1 is an X-linked nuclear protein involved in cell cycle regulation and growth control. It localizes to the nucleus and contains nucleic acid-binding RAGNYA folds that enable protein dimerization 1. The protein functions in cell cycle progression, as demonstrated by studies showing that AMMECR1 silencing suppresses lung cancer cell proliferation, arrests cells in S and G2/M phases, reduces colony formation, and promotes apoptosis 2. AMMECR1 is coexpressed with genes implicated in cell cycle regulation 1 and represents a novel genetic cause of short stature 3. Loss-of-function mutations in AMMECR1 cause a recognizable syndromic phenotype characterized by short stature, midface hypoplasia, developmental delay, sensorineural hearing loss, and elliptocytosis 145. Additional features include cardiac and skeletal abnormalities, nephrocalcinosis, cleft palate, and congenital hip dysplasia 16. AMMECR1 mutations are part of the AMME complex (Alport syndrome, mental retardation, midface hypoplasia, elliptocytosis) mapped to Xq22.3 74. Notably, pathogenic variants in AMMECR1 alone account for most AMME features except Alport syndrome 4, and AMMECR1 is expressed in fetal inner ear, explaining hearing loss in affected individuals 6.

Sources cited
1
AMMECR1 silencing suppresses lung cancer cell proliferation, reduces colony formation, promotes apoptosis, and causes cell-cycle arrest in S and G2/M phases
PMID: 31519561
2
AMMECR1 loss-of-function causes short stature, cardiac and skeletal abnormalities, hearing loss; protein contains nucleic acid-binding RAGNYA folds and dimerizes in the nucleus; is coexpressed with cell cycle regulation genes
PMID: 29193635
3
AMMECR1 is a novel genetic cause of syndromic short stature
PMID: 29787394
4
AMMECR1 is part of the AMME syndrome deletion at Xq22.3 and has murine orthologs with high amino acid identity
PMID: 10828604
5
AMMECR1 haploinsufficiency causes midface hypoplasia, intellectual disability, elliptocytosis, hearing loss, and short stature; AMMECR1 is responsible for most AMME features except Alport syndrome
PMID: 30737907
6
AMMECR1 missense mutations cause midface hypoplasia, intellectual disability, elliptocytes, and may contribute to nephrocalcinosis and cleft palate; mutant protein shows aberrant nuclear localization
PMID: 27811305
7
AMMECR1 is expressed in human fetal inner ear; mutations cause hearing loss, cleft palate, and congenital hip dysplasia in carriers
PMID: 35084080
8
AMMECR1 mutations cause X-linked elliptocytosis with impaired growth, midface hypoplasia, and hearing loss
PMID: 28089922
Disease Associationsβ“˜22
Alport syndrome - intellectual disability - midface hypoplasia - elliptocytosisOpen Targets
0.71Strong
Short statureOpen Targets
0.45Moderate
nephrocalcinosisOpen Targets
0.27Weak
neurodegenerative diseaseOpen Targets
0.19Weak
Alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndromeOpen Targets
0.19Weak
hypogonadismOpen Targets
0.10Weak
adolescent idiopathic scoliosisOpen Targets
0.02Suggestive
psoriasisOpen Targets
0.02Suggestive
lung cancerOpen Targets
0.01Suggestive
ovarian carcinomaOpen Targets
0.01Suggestive
Global developmental delayOpen Targets
0.01Suggestive
Alport syndromeOpen Targets
0.01Suggestive
cleft palateOpen Targets
0.01Suggestive
cancerOpen Targets
0.01Suggestive
neoplasmOpen Targets
0.01Suggestive
hepatocellular carcinomaOpen Targets
0.01Suggestive
Skraban-Deardorff syndromeOpen Targets
0.01Suggestive
deafnessOpen Targets
0.01Suggestive
primary myelofibrosisOpen Targets
0.01Suggestive
Intellectual disabilityOpen Targets
0.01Suggestive
AMME complexUniProt
Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosisUniProt
Pathogenic Variants14
NM_015365.3(AMMECR1):c.454dup (p.Arg152fs)Pathogenic
not provided|Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis
β˜…β˜…β˜†β˜†2023β†’ Residue 152
NM_015365.3(AMMECR1):c.220del (p.Gln74fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 74
NM_015365.3(AMMECR1):c.649G>A (p.Val217Met)Likely pathogenic
Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis
β˜…β˜†β˜†β˜†2025β†’ Residue 217
NM_015365.3(AMMECR1):c.491G>A (p.Trp164Ter)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 164
NM_015365.3(AMMECR1):c.756del (p.Ala253fs)Pathogenic
Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis
β˜…β˜†β˜†β˜†2024β†’ Residue 253
NM_015365.3(AMMECR1):c.805C>T (p.Gln269Ter)Pathogenic
Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis
β˜…β˜†β˜†β˜†2024β†’ Residue 269
NM_015365.3(AMMECR1):c.790+1G>ALikely pathogenic
Nephrocalcinosis
β˜…β˜†β˜†β˜†2024
NM_015365.3(AMMECR1):c.887+2T>ALikely pathogenic
Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis
β˜…β˜†β˜†β˜†2023
NM_015365.3(AMMECR1):c.429T>A (p.Tyr143Ter)Likely pathogenic
Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis
β˜…β˜†β˜†β˜†2020β†’ Residue 143
NM_015365.3(AMMECR1):c.794G>A (p.Trp265Ter)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2020β†’ Residue 265
NM_015365.3(AMMECR1):c.433_448del (p.Tyr145fs)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2018β†’ Residue 145
NM_015365.3(AMMECR1):c.888-610_*1821delLikely pathogenic
Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis
β˜†β˜†β˜†β˜†2023
NM_015365.3(AMMECR1):c.530G>A (p.Gly177Asp)Pathogenic
Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis
β˜†β˜†β˜†β˜†2017β†’ Residue 177
NM_015365.3(AMMECR1):c.454del (p.Arg152fs)Pathogenic
Short stature
β˜†β˜†β˜†β˜†2001β†’ Residue 152
View on ClinVar β†—
Related Genes
ACSL4Protein interaction94%COL4A5Protein interaction86%GUCY2FProtein interaction81%NXT2Protein interaction81%KCNE5Protein interaction80%
Tissue Expression6 tissues
Bone Marrow
100%
Ovary
43%
Lung
24%
Liver
20%
Brain
16%
Heart
8%
Gene Interaction Network
Click a node to explore
AMMECR1ACSL4COL4A5GUCY2FNXT2KCNE5
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q9Y4X0
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.35Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.13 [0.06–0.35]
RankingsWhere AMMECR1 stands among ~20K protein-coding genes
  • #11,462of 20,598
    Most Researched32
  • #2,539of 5,498
    Most Pathogenic Variants14
  • #1,504of 17,882
    Most Constrained (LOEUF)0.35 Β· top 10%
Genes detectedAMMECR1
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
PMID: 31519561
Anticancer Res Β· 2019
1.00
2
Inactivation of AMMECR1 is associated with growth, bone, and heart alterations.
PMID: 29193635
Hum Mutat Β· 2018
0.90
3
New developments in the genetic diagnosis of short stature.
PMID: 29787394
Curr Opin Pediatr Β· 2018
0.80
4
Identification and characterization of mouse orthologs of the AMMECR1 and FACL4 genes deleted in AMME syndrome: orthology of Xq22.3 and MmuXF1-F3.
PMID: 10828604
Cytogenet Cell Genet Β· 2000
0.70
5
Xq22.3q23 microdeletion harboring TMEM164 and AMMECR1 genes: Two case reports confirming a recognizable phenotype with short stature, midface hypoplasia, intellectual delay, and elliptocytosis.
PMID: 30737907
Am J Med Genet A Β· 2019
0.60